Pharmacological strategies to decrease excessive blood loss in cardiac surgery:: a meta-analysis of clinically relevant endpoints

被引:355
作者
Levi, M
Cromheecke, ME
de Jonge, E
Prins, MH
de Mol, BJM
Briët, E
Büller, HR
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Cardiopulm Surg, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/S0140-6736(99)01264-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Excessive bleeding may complicate cardiac surgery, and is associated with increased morbidity and mortality. Pharmacological strategies to decrease perioperative bleeding have been investigated in a large number of controlled trials, most of which have shown a decrease in blood loss. However, most studies lacked sufficient power to detect a beneficial effect on clinically more relevant outcomes. We did a meta-analysis of all randomised, controlled trials of the three most frequently used pharmacological strategies to decrease perioperative blood loss (aprotinin, lysine analogues [aminocaproic acid and tranexamic acid], and desmopressin). Methods Studies were included if they reported at least one clinically relevant outcome (mortality, rethoracotomy, proportion of patients receiving a transfusion, or perioperative myocardial infarction) in addition to perioperative blood loss. In addition, a separate meta-analysis was done for studies concerning complicated cardiac surgery. Findings We identified 72 trials (8409 patients) that met the inclusion criteria. Treatment with aprotinin decreased mortality almost two-fold (odds ratio 0.55 [95% CI 0.34-0.90]) compared with placebo. Treatment with aprotinin and with lysine analogues decreased the frequency of surgical re-exploration (0.37 [0.25-0.55] and 0.44 [0.22-0.90], respectively). These two treatments also significantly decreased the proportion of patients receiving any allogeneic blood transfusion. By contrast, the use of desmopressin resulted in a small decrease in perioperative blood loss, but was not associated with a beneficial effect on other clinical outcomes. Aprotinin and lysine analogues did not increase the risk of perioperative myocardial infarction; however, desmopressin was associated with a 2.4-fold increase in the risk of this complication. Studies in patients undergoing complicated cardiac surgery showed similar results. Interpretation Pharmacological strategies that decrease perioperative blood loss in cardiac surgery, in particular aprotinin and lysine analogues, also decrease mortality, the need for rethoracotomy, and the proportion of patients receiving a blood transfusion.
引用
收藏
页码:1940 / 1947
页数:8
相关论文
共 105 条
[1]   Analyses of coronary graft patency after aprotinin use: Results from the international multicenter aprotinin graft patency experience (IMAGE) trial [J].
Alderman, EL ;
Levy, JH ;
Rich, JB ;
Nili, M ;
Vidne, B ;
Schaff, H ;
Uretzky, G ;
Pettersson, G ;
Thiis, JJ ;
Hantler, CB ;
Chaitman, B ;
Nadel, A .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 116 (05) :716-729
[2]   THE USE OF ULTRA-LOW-DOSE APROTININ TO REDUCE BLOOD-LOSS IN CARDIAC-SURGERY [J].
ALVAREZ, JM ;
QUINEY, NF ;
MCMILLAN, D ;
JOSCELYNE, K ;
CONNELY, T ;
BRADY, P ;
DEAL, C ;
WILSON, R .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1995, 9 (01) :29-33
[3]   EFFECTS OF DESMOPRESSIN ACETATE ON PLATELET-AGGREGATION, VONWILLEBRAND-FACTOR, AND BLOOD-LOSS AFTER CARDIAC-SURGERY WITH EXTRACORPOREAL-CIRCULATION [J].
ANDERSSON, TLG ;
SOLEM, JO ;
TENGBORN, L ;
VINGE, E .
CIRCULATION, 1990, 81 (03) :872-878
[4]  
ANSELL J, 1992, J THORAC CARDIOV SUR, V104, P117
[5]  
Baele P L, 1992, Acta Anaesthesiol Belg, V43, P103
[6]  
BAILEY CR, 1994, BRIT HEART J, V71, P349
[7]   RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND-STUDY OF 3 APROTININ REGIMENS IN PRIMARY CARDIAC-SURGERY [J].
BAILEY, CR ;
KELLEHER, AA ;
WIELOGORSKI, AK .
BRITISH JOURNAL OF SURGERY, 1994, 81 (07) :969-973
[8]   Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations - A randomized, blinded clinical trial [J].
BennettGuerrero, E ;
Sorohan, JG ;
Gurevich, ML ;
Kazanjian, PE ;
Levy, RR ;
Barbera, AV ;
White, WD ;
Slaughter, TF ;
Sladen, RN ;
Smith, PK ;
Newman, MF .
ANESTHESIOLOGY, 1997, 87 (06) :1373-1380
[9]  
BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364
[10]   EFFECT OF APROTININ (TRASYLOL) ON AORTA-CORONARY BYPASS GRAFT PATENCY [J].
BIDSTRUP, BP ;
UNDERWOOD, SR ;
SAPSFORD, RN .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 105 (01) :147-153